Recombinant human growth hormone (rhGH, somatropin) is a 191-amino-acid polypeptide identical in sequence to the human pituitary-derived growth hormone, produced via recombinant DNA technology in Escherichia coli (most commonly) or mammalian cell-culture systems. It is among the most studied biologic medicines, with approvals across paediatric growth-hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic renal insufficiency, adult GH deficiency and HIV-associated wasting. Beyond its approved indications, rhGH is a primary research tool for studying the GH/IGF-1 axis, body-composition pharmacology and the broader endocrine pathways governing protein synthesis, lipolysis and glucose metabolism.
Recombinant human growth hormone binds the growth hormone receptor (GHR), a single-transmembrane receptor that dimerises upon ligand binding and activates intracellular JAK2 tyrosine kinase. Downstream signalling proceeds through the STAT5 transcription factor, the PI3K/Akt pathway and the Ras/MAPK pathway — collectively driving the anabolic, lipolytic and metabolic effects classically associated with the GH axis.
A major fraction of rhGH's downstream physiologic effects are mediated indirectly through IGF-1 production at the liver (and other tissues). rhGH-induced hepatic IGF-1 synthesis is the principal anabolic effector for skeletal growth in paediatric indications and for body-composition changes in adult research.
Compared with the GHRH-axis compounds (sermorelin, tesamorelin, CJC-1295) and the ghrelin-receptor agonists (ipamorelin, hexarelin), rhGH bypasses the entire pituitary regulatory loop — it is direct receptor agonism rather than upstream stimulation of endogenous release. This is the principal pharmacologic distinction that makes rhGH a clinical product across multiple indications while its upstream stimulants remain primarily research tools.
Recombinant hGH (Genotropin, Humatrope, Norditropin, Saizen and others) is approved across paediatric growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, idiopathic short stature, chronic renal insufficiency with growth failure, SHOX gene deficiency, adult GH deficiency, and HIV-associated wasting. The clinical evidence base is among the deepest of any biologic medicine.
The compound is also extensively studied in non-approved research lines including frailty in older adults, post-burn catabolism, fibromyalgia, and athletic performance research (where it remains WADA-prohibited).
Beyond clinical indications, rhGH is the standard research tool for studying GH-receptor pharmacology, the JAK2/STAT5 signalling cascade, GH-IGF-1 axis regulation and body-composition pharmacology. In cell culture, rhGH is the standard ligand for GHR activation studies.
Combination research with GHRH analogues (e.g. tesamorelin) and GHRPs (e.g. ipamorelin) has explored whether stimulating endogenous release alongside exogenous rhGH produces different physiologic profiles — an active research line examining the contributions of GH pulse architecture vs total exposure.